Engineering better medicines. Conquering drug limitations.
Valitor is conquering limitations of established drug targets by leveraging its multi-valent biopolymer
technology to maximize benefits for patients.
The company is engineering disruptive medicines that optimize how and where disease mechanisms are targeted to produce the most significant clinical
Valitor is initially focused on improving patient outcomes in ophthalmology and vision- threatening diseases.
Our core technology platform originated at UC Berkeley and enables us to generate multivalent protein (MVP) conjugates by tethering multiple copies of bioactive molecules (e.g., camelid antibodies, cytokines, etc.) to single-chain, soluble biopolymers. Using Valitor’s propriety compositions and chemistry methods, our MVPs exhibit the following advantages over other therapeutic products that are either on the market or in development:
Proteins / peptides
Antibodies / Fabs
BioBetter features of MVP conjugates:
Extended Target Tissue Retention
Protection from Deactivation
Superior Safety Profile